Trials / Unknown
UnknownNCT01111981
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Callender Center for Clinical Research · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to ascertain the safety and efficacy of Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal Cicatricial Alopecia.
Detailed description
Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced hair loss starting in the central scalp and progressing centrifugally. The cause of CCCA is unknown. Early diagnosis and treatment is essential to stop or slow the progression of scarring and permanent hair loss. Once scarring occurs, the hair follicles are obliterated and the hair cannot regrow. Thus, anti-inflammatory medications are used to decrease inflammation. Current treatment includes topical and intralesional corticosteroids, oral antibiotics, and hair transplantation, all which may take months to years to show improvement. There is no evidence-based medicine on how to treat primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is an FDA-approved and marketed topical corticosteroid for the treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid- responsive dermatoses of the scalp. Many studies found the foam to be less irritating than the original formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clobetasol Propionate 0.05% Emollient Foam | Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-02-01
- Completion
- 2010-10-01
- First posted
- 2010-04-28
- Last updated
- 2010-04-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01111981. Inclusion in this directory is not an endorsement.